BioTime, Inc. Announces Pricing of $25.0 Million Public Offering of Common Stock
October 13 2017 - 9:15AM
Business Wire
BioTime, Inc. (“BioTime”) (NYSE American and TASE: BTX), a late
stage clinical biotechnology company focused on developing and
commercializing products addressing degenerative diseases, today
announced the pricing of an underwritten public offering of
9,615,385 shares of its common stock at a public offering price of
$2.60 per share. The gross proceeds to BioTime from this offering
are expected to be approximately $25.0 million, before deducting
underwriting discounts and commissions and other estimated offering
expenses payable by BioTime. The offering is expected to close on
or about October 17, 2017, subject to customary closing conditions.
BioTime has also granted to the underwriters a 30-day option to
purchase from it up to an aggregate of an additional 1,442,308
shares of its common stock, to cover over allotments, if any.
BioTime intends to use the net proceeds from this offering for
general corporate purposes, including, without limitation, to fund
clinical trials, to finance research and develop programs, and for
general working capital.
Raymond James & Associates, Inc. is acting as the sole
book-running manager for the offering. Ladenburg Thalmann & Co.
Inc., Chardan and LifeSci Capital LLC are acting as
co-managers. Lake Street Capital Markets is acting as a
financial advisor for the offering.
The shares will be offered pursuant to an effective registration
statement on Form S-3 (File No. 333-217182) that was previously
filed with the Securities and Exchange Commission (the “SEC”) and
became effective on May 5, 2017. A preliminary prospectus
supplement and the related prospectus have been filed with the SEC
and are available on the SEC’s website at www.sec.gov. A final
prospectus supplement and the related prospectus will be filed with
the SEC and available on the SEC’s website at www.sec.gov. Copies
of the prospectus supplement and accompanying prospectus relating
to the offering may be obtained, when available, from Raymond James
& Associates, Inc., Attention: Equity Syndicate, 880 Carillon
Parkway, St. Petersburg, Florida 33716, or by telephone at (800)
248-8863, or e-mail at prospectus@raymondjames.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such an
offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of any such state or
jurisdiction.
About BioTime, Inc.
BioTime is a late stage clinical biotechnology company focused
on developing and commercializing products addressing degenerative
diseases. The Company’s current clinical programs are targeting
three primary sectors: aesthetics, ophthalmology and cell and drug
delivery.
Forward-Looking Statements
Certain statements contained in this release are
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. Investors are cautioned
that statements in this press release regarding the anticipated
amount and use of the proceeds of the offering and the completion
of the public offering constitute forward-looking statements that
involve risks and uncertainties, including, without limitation,
risks and uncertainties related to market conditions and the
satisfaction of customary closing conditions related to the
proposed public offering. There can be no assurance
that BioTime will be able to complete the proposed public
offering. Additional information on risks facing BioTime, its
subsidiaries and its affiliates can be found in the “Risk
Factors” section of its Annual Reports on Form 10-K and Quarterly
Reports on Form 10-Q filed with the Securities and Exchange
Commission (the “SEC”) and in the preliminary prospectus supplement
related to the proposed offering to be filed with
the SEC on or about the date hereof (copies of which may
be obtained at www.sec.gov). Subsequent events and developments may
cause these forward-looking statements to change. BioTime
specifically disclaims any obligation or intention to update or
revise these forward-looking statements as a result of changed
events or circumstances that occur after the date of this release,
except as required by applicable law.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171013005344/en/
Investor Contact:BioTimeDavid Nakasone,
510-871-4188DNakasone@biotimeinc.comorMedia Contact:JQA
Partners, Inc.Jules Abraham,
917-885-7378jabraham@jqapartners.com
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Apr 2023 to Apr 2024